CTRI/2023/08/056121
Not Yet Recruiting
N/A
A clinical evaluation of the add on effectiveness of a set of therapeutic asanas in low backache. - nil
Dr Jency Babu0 sites0 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Health Condition 1: M958- Other specified acquired deformities of musculoskeletal system
- Sponsor
- Dr Jency Babu
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects fulfilling at least one of the diagnostic criteria.
- •Ready to sign informed consent
Exclusion Criteria
- •History of spinal surgeries.
- •Pregnant women
- •Known case of disc slip, osteoporosis, disc desiccation, spondylolisthesis.
- •Subjects those who cannot follow the command.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 2
Ayurvedic management of low back with granulesHealth Condition 1: M545- Low back painCTRI/2024/07/069921Sri Dharmasthala Munjunathesheswara College ofAyurveda and Hospital
Not Yet Recruiting
Phase 2
To study the add on effectiveness of khadira yavagu as food in the management of dadru kushta(tinea)Health Condition 1: - Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2020/11/029372Dr Arsha K S
Not Yet Recruiting
Phase 2
To study the add on effectiveness of Palandu peya as a food in the management of Raktapradara(Menorrhagia)Health Condition 1: N920- Excessive and frequent menstruation with regular cycleCTRI/2020/01/022839Dr Reshma Shaji
Not Yet Recruiting
Phase 2
Managing Acidity With Unripe Bilwa Phala Panaka As Diet SupplementHealth Condition 1: K210- Gastro-esophageal reflux disease with esophagitisCTRI/2024/06/069455Sri Dharmasthala Manjunatheswara College Of Ayurveda And Hospital
Not Yet Recruiting
N/A
A study to assess the clinical effectiveness and safety of intravesical mitomycin-C and gemcitabine sequential therapy in patients with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) Therapy: Prospective, multicenter, open-label trialKCT0009491ational Cancer Center82